Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cronos Group Inc (CRON) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance

Cronos Group IncTrade
Marsh & McLennan Companies, Inc.Trade

Price performance (Past 24H)

Key statistics

Cronos Group Inc vs Marsh & McLennan Companies, Inc. — how do they compare? Cronos Group Inc trades at $3.08 (market cap $1.14B), while Marsh & McLennan Companies, Inc. trades at $191.32 (market cap $91.27B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 80.1× Cronos Group Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.07% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.

CRONMRSH
Market Cap
$1.14B$91.27B
Sector
HealthFinancials
52-Week High
$3.27$211.21
52-Week Low
$2.30$157.32
Enterprise Value
$341.13M$111.95B
Dividend Yield
2.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cronos Group Inc

CRON trades at $3.165, up 5.5% with bullish technical signals from moving averages. The company shows strong revenue growth, with Q2 2026 beating expectations with $0.09 EPS versus $0.01 expected, and record quarterly performance. However, profitability remains inconsistent with negative net income in 2025. Analyst sentiment is mixed with 60% hold ratings, reflecting cautious optimism amid competitive pressures.

Outlook is cautiously optimistic with international expansion driving growth, but execution risks and cannabis sector volatility persist. The stock offers growth potential through European market penetration and product innovation, though investors should monitor margin improvements and competitive dynamics closely.

Marsh & McLennan Companies, Inc.

Marsh & McLennan (MRSH) trades at $188.81, down 1.04% today, but maintains a bullish technical trend with strong fundamentals. The company reported Q2 2026 EPS of $2.96, beating estimates, and has consistently exceeded earnings expectations. Revenue growth remains solid at 6% in Q2 2026, driven by risk and consulting services. Recent acquisitions, like the planned purchase of Accel Holdings, aim to expand its Midwest insurance reach.

The outlook is positive with a consensus price target of $202.89, suggesting 7.5% upside. Risks include margin pressure from rising expenses and soft P&C pricing. Analyst sentiment is mixed with 30.3% buy ratings but 66.7% hold, indicating cautious optimism. Institutional activity shows new positions by Ashton Thomas Securities and Bank of Nova Scotia, supporting long-term growth prospects.

Returns comparison

Trailing returns across standard periods

About Cronos Group Inc

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.

Read more on CRON

About Marsh & McLennan Companies, Inc.

Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).

Read more on MRSH